First report on a series of HIV patients undergoing rapamycin monotherapy after liver transplantation

Transplantation

Volumn 89, Issue 6, 2010, Pages 733-738

  Di Benedetto, Fabrizio ^a   Di Sandro, Stefano ^a   De Ruvo, Nicola ^a   Montalti, Roberto ^a   Ballarin, Roberto ^a   Guerrini, Gian Piero ^a   Spaggiari, Mario ^a   Guaraldi, Giovanni ^a   Gerunda, Giorgio ^a  

^a UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

Author keywords

HAART; HIV patients; Liver transplantation; Rapamycin.

Indexed keywords

AMPICILLIN; CALCINEURIN INHIBITOR; CEPHALOSPORIN; COTRIMOXAZOLE; CYCLOSPORIN A; FLUCONAZOLE; GANCICLOVIR; HEPATITIS B ANTIBODY; LAMIVUDINE; METHYLPREDNISOLONE; PEGINTERFERON; RAPAMYCIN; RIBAVIRIN; TACROLIMUS; TENOFOVIR; VIRUS RNA;

ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; CLINICAL ARTICLE; CLINICAL TRIAL; CYTOMEGALOVIRUS INFECTION; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; GLUCOSE INTOLERANCE; HEPATITIS B; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERTENSION; INFECTION CONTROL; KAPOSI SARCOMA; LIVER CELL CARCINOMA; LIVER DISEASE; LIVER GRAFT REJECTION; LIVER TRANSPLANTATION; LOADING DRUG DOSE; MALE; MONOTHERAPY; MYCOSIS; NEPHROTOXICITY; NEUROTOXICITY; PNEUMOCYSTOSIS; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; PROPHYLAXIS; VIRUS REPLICATION;

ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; FEMALE; GRAFT REJECTION; GRAFT SURVIVAL; HEPACIVIRUS; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HIV INFECTIONS; HIV-1; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KAPLAN-MEIERS ESTIMATE; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RNA, VIRAL; SIROLIMUS; TIME FACTORS; TREATMENT OUTCOME; VIRAL LOAD;

EID: 77949908335     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e3181c7dcc0     Document Type: Article

References (26)

1. Abraham RT, Wiederrecht GJ. Immunopharmacology of rapamycin. Annu Rev Immunol 1996; 14: 483.
2. Molnar-Kimber KL. Mechanism of action of rapamycin (Sirolimus, Rapamune). Transplant Proc 1996; 28: 964.
3. Chiu MI, Katz H, Berlin V. RAPT1, a mammalian homolog of yeast Tor, interacts with the FKBP12/rapamycin complex. Proc Natl Acad Sci USA 1994; 91: 12574.
4. Brunn GJ, Hudson CC, Sekulic A, et al. Phosphorylation of the trans-lational repressor PHAS-I by the mammalian target of rapamycin. Science 1997; 277: 99.
5. Thomas G, Hall MN. TOR signalling and control of cell growth. Curr Opin Cell Biol 1997; 9: 782.
6. Liu R, Paxton WA, Choe S, et al. Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection. Cell 1996; 86: 367.
7. Lin YL, Mettling C, Portales P, et al. Cell surface CCR5 density determines the postentry efficiency of R5 HIV-1 infection. Proc Natl Acad Sci USA 2002; 99: 15590.
8. + lymphocytes in vivo. J Infect Dis 2000; 181: 933.
9. Heredia A, Amoroso A, Davis C, et al. Rapamycin causes down-regulation of CCR5 and accumulation of anti-HIV beta-chemokines: An approach to suppress R5 strains of HIV-1. Proc Natl Acad Sci USA 2003; 100:10411.
10. Mazzaferro V, Regalia E, Doci R, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 1996; 334: 693.
11. Yao FY, Ferrell L, Bass NM, et al. Liver transplantation for hepatocellular carcinoma: Expansion of the tumor size limits does not adversely impact survival. Hepatology 2001; 33:1394.
12. Pawarode A, Fine DM, Thuluvath PJ. Independent risk factors and natural history of renal dysfunction in liver transplant recipients Liver Transpl2003; 9: 741.
13. Toso C, Meeberg GA, Bigam DL, et al. De novo sirolimus-based immunosuppression after liver transplantation for hepatocellular carcinoma: Long-term outcomes and side effects. Transplantation 2007; 83:1162.
14. Kneteman NM, Oberholzer J, Al Saghier M, et al. Sirolimus-based immunosuppression for liver transplantation in the presence of extended criteria for hepatocellular carcinoma. Liver Transpl 2004; 10: 1301.
15. Di Benedetto F, Di Sandro S, De Ruvo N, et al. Kaposi's sarcoma after liver transplantation. J Cancer Res Clin Oncol 2008; 134: 653.
16. Duclos-Vallee JC, Vittecoq D, Teicher E, et al. Hepatitis C virus viral recurrence and liver mitochondrial damage after liver transplantation in HIV-HCV co-infected patients. J Hepatol 2005; 42: 341.
17. Samonakis DN, Cholongitas E, Triantos CK, et al. Sustained, spontaneous disappearance of serum HCV-RNA under immunosuppression after liver transplantation for HCV cirrhosis. J Hepatol 2005; 43: 1091.
18. Trkola A, Kuhmann SE, Strizki JM, et al. HIV-1 escape from a small molecule, CCR5-specific entry inhibitor does not involve CXCR4 use. Proc Natl Acad Sci USA 2002; 99: 395.
19. Lederman MM, Veazey RS, Offord R, et al. Prevention of vaginal SHIV transmission in rhesus macaques through inhibition of CCR5. Science 2004; 306: 485.
20. Veazey RS, Klasse PJ, Ketas TJ, et al. Use of a small molecule CCR5 inhibitor in macaques to treat simian immunodeficiency virus infection or prevent simian-human immunodeficiency virus infection. J Exp Med 2003; 198: 1551.
21. Ray N, Doms RW. HIV-1 coreceptors and their inhibitors. Curr Top Microbiol Immunol 2006; 303: 97.
22. Gilliam BL, Heredia A, Devico A, et al. Rapamycin reduces CCR5 mRNA levels in macaques: Potential applications in HIV-1 prevention and treatment. AIDS 2007; 21: 2108.
23. Roy J, Paquette JS, Fortin JF, et al. The immunosuppressant rapamycin represses human immunodeficiency virus type 1 replication. Antimi-crob Agents Chemother 2002; 46: 3447.
24. Heredia A, Gilliam B, Latinovic O, et al. Rapamycin reduces CCR5 density levels on CD4 T cells, and this effect results in potentiation of enfuvirtide (T-20) against R5 strains of human immunodeficiency virus type 1 in vitro. Antimicrob Agents Chemother 2007; 51: 2489.
25. Moreno A, Barcena R, Quereda C, et al. Safe use of raltegravir and sirolimus in an HIV-infected patient with renal impairment after orthotopic liver transplantation. AIDS 2008; 22: 547.
26. Heredia A, Davis C, Amoroso A, et al. Induction of G1 cycle arrest in T lymphocytes results in increased extracellular levels of beta-chemokines: A strategy to inhibit R5 HIV-1. Proc Natl Acad Sci USA2003; 100:4179.